News
UCBJF
259.59
NaN%
--
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
Seeking Alpha · 3d ago
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment
Seeking Alpha · 08/27 16:29
Protagonist upgraded at Goldman Sachs on potential of autoimmune asset
Seeking Alpha · 08/10 15:42
TD Cowen Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 08/04 08:57
UBS Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 08/04 08:56
Stacy Ku Initiates Buy on UCB, Citing Attractive Valuation and Early Bimzelx-Driven Growth Inflection
TipRanks · 08/03 08:55
UCB upgraded to Hold from Underperform at Jefferies
TipRanks · 08/03 08:20
Barclays Sticks to Their Hold Rating for UCB SA (0NZT)
TipRanks · 08/03 07:15
Hold Rating Maintained as De-Rated Valuation Balances Risk-Reward; Price Target Raised from $212 to $220 on Improved EBITDA Outlook Amid Ongoing Bimzelx Concerns
TipRanks · 08/03 06:05
UCB SA (0NZT) Receives a Buy from Goldman Sachs
TipRanks · 08/03 05:35
UCB SA Non-GAAP EPS of €6.84, revenue of €4.27B; updates FY2026 outlook
Seeking Alpha · 07/30 07:14
UCB: From Rebuild To Re-Rating (Initiating Buy)
Seeking Alpha · 07/17 15:00
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Seeking Alpha · 07/17 04:10
UCB Data Reinforce Long-Term Promise For Weak Muscles Disorder
Benzinga · 07/08 12:46
UCB price target raised to EUR 305 from EUR 290 at Berenberg
TipRanks · 07/02 16:15
Jefferies Keeps Their Sell Rating on UCB SA (0NZT)
TipRanks · 06/22 13:18
UCB downgraded to Equal Weight from Overweight at Barclays
TipRanks · 06/15 08:45
Barclays downgrades UCB SA (0NZT) to a Hold
TipRanks · 06/15 07:15
UCB SA (0NZT) Receives a Buy from UBS
TipRanks · 06/09 08:45
UCB SA (0NZT) Gets a Buy from Barclays
TipRanks · 05/28 06:46
More
Webull provides a variety of real-time UCBJF stock news. You can receive the latest news about Ucb Sa through multiple platforms. This information may help you make smarter investment decisions.
About UCBJF
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.